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Abstract
Background: Extra-capsular growth (ECG) describes the extension of neoplastic cells beyond the lymph node
capsule. Aim of this study was to investigate the prognostic value of ECG and its association with a stem cell like
phenotype indicated by expression of the transcription factor SOX9 in gastric cancer.
Methods: By histological evaluation, 199 patients with nodal positive gastric cancer or adeoncarcinoma of the
esophageal-gastric junction (AEG) were divided into two groups according to the presence (ECG) or absence (ICG)
of extracapsular growth in at least one nodal metastasis. Of these, 194 patients were stained for SOX9 and SOX2
using immunohistochemistry. Seventeen nodal negative patients (pT3/4, pN0, pM0) served as controls.
Results: Seventy-three patients (36.7%) showed ECG. ECG was associated with lower overall survival (p < 0.0001),
advanced pT- (p = 0.03) and pN- category (p < 0.0001) and lymphovascular invasion (p = 0.014). In multivariate
analysis, ECG was found to be an independent prognostic factor (HR = 2.1; 95% CI 1.7–3.4; p = 0.001). SOX9
expression correlated significantly with ECG (96% SOX9 high in ECG patients vs. 79% SOX9 high in patients with
ICG; p = 0.002). Controls showed significantly reduced SOX9 expression compared to nodal positive carcinomas
(59% vs. 85% high SOX9 expression; p = 0.006). No significant correlation of ECG and SOX2 (59% SOX2 negative in
ECG patients vs. 64% in patients with ICG, p = 0.48) could be obtained.
Conclusions: Patients with ECG exhibit poorer prognosis and ECG was found to be an independent prognostic
factor. Thus, ECG turns out to be a morphological biomarker for a more aggressive phenotype in gastric cancer.
This is supported by the fact that ECG correlates with the expression of SOX9, which has been described in the
context of pro-oncogenic properties of tumours. However, the fact that SOX2 failed to show significant results
indicate that ECG is not associated with a distinct cancer stem cell phenotype in gastric cancer.
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Background
The extra-capsular growth (ECG) describes the exten-
sion of neoplastic cells beyond the lymph node capsule
into the perinodular soft tissue. Being a prognostic factor
for cancer in several organs [1, 2] including the gastro-
intestinal tract [3, 4], ECG has already found access to
staging systems such as the squamous cell carcinoma of
the vulva and the head and neck [5].
A systematic review about colorectal cancer deter-
mined ECG to be associated with poorer prognosis and
a higher risk of recurrence of disease [6]. Therefore, the
parameter ECG is also suggested to be included as a
prognostic parameter in colorectal cancer staging sys-
tems [6]. In gastric cancer, ECG is associated with
poorer 5-year survival and was also found to be an inde-
pendent prognostic factor [4, 7]. ECG is associated with
larger tumour size, advanced pT- and pN-category and
lymphovascular and perineural invasion [4, 7].
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Both SOX9 and SOX2 are members of the DNA- bind-
ing HMG domain proteins and part of the SOX-family of
transcription factors. SOX2 is mainly involved in the regu-
lation of embryonic development and in the determin-
ation of cell fate. Besides being required for the stem-cell
maintenance in the central nervous system, SOX2 is
known to regulate gene expression in the stomach [8]. In
gastric cancer, high expression of SOX2 was found to be
associated with decreased rates of lymph node metastasis
and better treatment outcome [9]. SOX9 is important for
sex determination as it initiates testis development. It also
plays a decisive role in chondrogenesis by regulating car-
tilage specific gene expression [10, 11]. In the gastrointes-
tinal tract, SOX9 is expressed in nuclei of crypt cells
including Paneth and stem cells [11], playing an important
role for endoderm development and homeostasis of the
intestinal epithelium by interacting with the Wnt/ß-ca-
tenin-signalling pathway. SOX9, together with the Wnt/ß-
catenin-target Slug, was found to determine the stem cell
state in mammary cells by inducing differentiated luminal
cells to pass through epithelial-mesenchymal transition
(EMT), thus driving malignant progression an metastasis
[12].
SOX9 is associated with poorer prognosis and ad-
vanced TNM category in different types of gastrointes-
tinal cancer [13, 14]. In colorectal cancer, high SOX9
expression was found to be an independent prognostic
factor [14]. Similar, in gastric cancer SOX9 over-
expression is related to tumour progression and associ-
ated with lower 5-year survival, tumour invasion as well
as advanced TNM category [15].
Based on these findings it was the aim of our study to
analyse the prognostic value of ECG in gastric cancer as
a morphological marker for a more aggressive tumour
phenotype. Furthermore, we intended to analyse the as-
sociation of ECG with the protein expression of the em-
bryonic transcription factors SOX9 and SOX2 both




From the data bank of the Department of General,
Visceral, Transplantation, Vascular and Thoracic
Surgery, Medical Center of the University of Munich,
529 patients who underwent surgery for gastric
cancer or adenocarcinoma of the esophageal-gastric
junction (AEG) between 2002 and 2014 were selected.
Cases with lymph node metastasis were extracted
(n = 260) and the histological slides of 199 of the 260
nodal positive cases could be collected from the archives
of the Institute of Pathology, Faculty of Medicine, LMU
Munich. Clinico-pathological parameters are summarized
in Table 1. The lymph node status was evaluated
according to standard protocols following the national
German guidelines. In brief, all lymph nodes included
in the surgical specimen were dissected. Lymph nodes
larger than 0.5 cm were divided in half and from each
lymph node specimen two to three serial sections
were prepared. In indistinct cases additional serial
sections were made.
Formalin fixed and paraffin embedded (FFPE) speci-
mens of the primary tumours of 194 of the 199 nodal
positive patients were collected for immunohisto-
chemistry. Seventeen locally advanced, nodal negative
Table 1 Correlation of the ECG/ICG-status with clinico-
pathological variables at time of surgery (according to TNM
Classification of Malignant Tumours 8th edition 2017).
Percent-values are given in parentheses
Capsule status
Characteristic Total (%) ECG ICG p
All patients 199 (100) 73 (36.7) 126 (63.3)
Age (median. 66.0) years
≤ 66 100 (50.3) 33 (16.6) 67 (33.7) 0.279
≥ 67 99 (49.7) 40 (20.1) 59 (29.6)
Gender
Male 128 (64.3) 41 (20.6) 87 (43.7) 0.067
Female 71 (35.7) 32 (16.1) 39 (19.6)
Lauren classification
diffuse 69 (34.7) 33 (16.6) 36 (18.1) 0.059
intestinal 108 (54.3) 33 (16.6) 75 (37.7)
mixed type 22 (11.1) 7 (3.5) 15 (7.5)
Tumor size (UICC)
T0 4 (2.0) 1 (0.5) 3 (1.5) 0.032
T1 2 (1.0) 0 (0) 2 (1.0)
T2 97 (48.7) 27 (13.6) 70 (35.2)
T3 61 (30.7) 25 (12.6) 36 (18.1)
T4 34 (17.1) 19 (9.5) 15 (7.5)
Tx 1 (0.5) 1 (0.5) 0 (0)
Nodal status
N0 0 (0) 0 (0) 0 (0) –
N+ 199 (100) 73 (36.7) 126 (63.3)
Distant metastasis
M0 126 (63.3) 41 (20.6) 85 (42.7) 0.179
M1 58 (29.1) 27 (13.6) 31 (15.6)
Mx 15 (7.5) 5 (2.5) 10 (5.0)
Tumor grade (WHO)
G1 2 (1.0) 1 (0.5) 1 (0.5) 0.207
G2 31 (15.6) 7 (3.5) 24 (12.1)
G3 162 (81.4) 63 (31.7) 99 (49.7)
Gx 4 (2.0) 2 (1.0) 2 (1.0)
Significant results are indicated by bold numbers
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patients without distant metastasis (pT3/4, pN0, pM0)
served as controls (Fig. 1). The histological slides of all
lymph node positive cases (n = 199) were evaluated by two
independent observers (JN and HL) according to the pres-
ence (ECG) or absence (ICG) of extracapsular growth in
at least one nodal metastasis (Fig. 2a-d).
Immunohistochemistry
Immunohistochemical stainings were performed using
5 μm serial tissue sections of representative FFPE
tumour samples. For SOX9 specific immunohisto-
chemistry first a heat-induced epitope retrieval was
done applying ProTaqs IV Anitgen-Enhancer (Quar-
tett, Germany) before adding primary SOX9 specific
rabbit monoclonal antibody (1:100, SOX9 clone
D8G8H, Cell Signalling Technology, Danvers, MA)
for 60 min at room temperature. Thereafter, a devel-
opment step was introduced by adding detection-
system (Vectastain ABC-Kit Elite Universal, Biozol,
Germany) and subsequently substrate-chromogen con-
taining DAB+ system (DAKO, Germany) according to
the respective manufacturer’s protocols.
For SOX2 specific immunohistochemistry heat-
induced epitope retrieval was performed applying Epi-
tope Retrieval Solution (Novocastra, Germany) followed
by adding primary SOX2 specific rabbit monoclonal
antibody (1:50, SOX2 clone D6D9, Cell Signalling Tech-
nology, Danvers, MA) for 60 min at room temperature.
The development step was made by adding the
detection-system (ImmPRESS Reagent Kit Anti-RABBIT
Ig, Vector, Germany) and substrate-chromogen contain-
ing DAB+ system (DAKO, Germany).
Finally, for both markers slides were counterstained
using Hematoxylin (Vector Laboratories, Burlingame,
CA). To control for unspecific binding of antibodies, iso-
type controls were included (data not shown).
Scoring of immunohistochemistry
Immunohistochemistry both for SOX9 and SOX2 were
evaluated independently by two observers (JN and HL).
Nuclear staining was reported for both, percentage and
intensity of stained nuclei throughout the tumour. Inten-
sity values were categorized as follows: no staining – 0,
weak–1, moderate – 2 and strong – 3. The staining of
SOX9 was evaluated as follows: when less than 30% of
tumour cells were stained and/or the intensity was miss-
ing (0) or weak (1), immunostaining was reported to be
negative (Fig. 3a and b). When less than 10% of tumour
cells were stained for SOX2 and/or the intensity was
missing (0) or weak (1), immunostaining was reported to
be negative (Fig. 3c and d). Discrepant cases were dis-
cussed and a consensus was reached.
Fig. 1 Flowchart showing the selection of nodal positive and nodal negative cases for histological evaluation of extra-capsular growth (ECG) and
intra-capsular growth (ICG) as well as for immunohistochemical analysis of SOX9 expression
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Fig. 2 Overview of lymph-node metastasis of gastric cancer with ECG (a) and ICG (b). The frames indicate areas shown with higher magnification
in c and d (200 fold, hematoxylin and eosin stain), respectively
Fig. 3 Immunhistochemical staining of SOX9 and SOX2 in gastric adenocarcinoma (200-fold magnification). In a adenocarcinoma with
high and in b with low immunohistochemical expression of SOX9 are shown. Adenocarcinoma with positive and negative SOX2
expression is shown in c and in d, respectively
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Statistics
All statistics were calculated using SPSS v.17.0 (SPSS
Inc.). Significance of correlations of the immunhisto-
chemical analyses was calculated using the χ2-test.
Survival analysis was performed using Kaplan-Meier-test
and multivariate Cox-regression. For all tests a p-value of
p < 0.05 was considered statistically significant.
Results
The average number of the lymph nodes being ob-
served was 24.4 (min. 3, max. 85). Seventy-three pa-
tients (36.7%) showed ECG (Fig. 4a). The mean
number of lymph nodes with ECG was 2.6 (min. 1,
max. 12). Presence of ECG was associated with sig-
nificantly lower overall survival (p < 0.0001; Fig. 4b).
Patients with ECG had a median survival of 16.
21 months (95% confidence interval (CI) 11.69–20.74;
standard deviation (SD) 2.31) whereas patients with-
out ECG had a median survival of 37.07 months (95%
CI 30.28–43.85;SD 3.46). In univariate analysis, cox-
regression detected a hazard ratio (HR) of 2.4 (95%
CI 1.7–3.4; p < 0.0001).
Regarding the subgroup of stage UICC II patients
(n = 76), ECG was also associated with significantly
lower overall survival (p = 0.001). The median survival
of stage II patients with ECG (n = 16) was 21.0 months
(95% CI 11.3–30.6; SD 5.0) whereas stage II patients
with ICG (n = 60) had a median survival of 50.7 months
(95% CI 39.0–62.4; SD 6.0). In univariate cox-regression,
the HR was 2.9 (95% CI 1.5–5.6; p = 0.001). In multi-
variate analysis, ECG was found to be a prognostic
factor (HR = 2.1; 95% CI 1.7–3.4; p = 0.001), independ-
ent from T- and N-category, UICC-stage and lym-
phangiosis carcinomatosa.
Presence of ECG was associated with advanced pT-
(p = 0.03; Fig. 5a) and pN-category (p < 0.0001; Fig. 5b)
but not with the presence of distant metastases (pM cat-
egory, p = 0.067; Fig. 5c). In category pT2 (n = 97), 28%
showed an ECG, whereas in category pT3 (n = 61) it was
41% and in pT3 (n = 34) even 56% (p = 0.03). The associ-
ation with pN-category was highly significant (p < 0.0001);
the percentage of cases with ECG doubled from cat-
egory pN1 to pN2 and tripled from pN1 to pN3
(pN1: n = 89, ECG 19%; pN2: n = 59, ECG = 41%; pN3:
n = 51, ECG = 63%).
ECG was further associated with lymphovascular in-
vasion. Forty-two percent of cases with lymphangiosis
carcinomatosa (L1, n = 143) showed ECG whereas
among patients without lymphangiosis carcinomatosa
(L0, n = 56) it was only 23% (Fig. 5d). The majority of
nodal positive cases were classified as SOX9-high
positive (n = 165, 85%; Fig. 3a). Twenty-nine patients
showed low or missing SOX9 expression and were
classified as negative (n = 29, 15%; Fig. 3b). Ten of
seventeen (59%) control cases showed high positive
SOX9 expression. In contrast to these results, the ma-
jority of nodal positive cases were classified as SOX2-
negative (n = 120, 62%, Fig. 3d). 74 patients showed
positive SOX2 expression (n = 74, 38%, Fig. 3c). Ten
of seventeen (59%) control cases showed negative
SOX2 expression.
SOX9 expression correlated significantly with ECG
(96% high positive SOX9 expression in ECG patients
vs. 79% high positive SOX9 expression in ICG pa-
tients; p = 0.002; Fig. 6a). The controls showed a sig-
nificantly lower rate of high positive SOX9 expression
compared to the nodal positive carcinomas (nodal
positive: 85% high positive SOX9 expression; control:
a b
Fig. 4 Proportion of cases with ECG and ICG (a) and its correlations with overall survival (b)
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59% (10/17); p = 0.006; Fig. 6b). Correlations of SOX9
expression with clinic-pathological parameters are
shown in Table 2. There was no significant correl-
ation between SOX2 expression and ECG (59% nega-
tive SOX2 expression in ECG patients vs. 64%
negative SOX2 expression in ICG patients, p = 0.48,
Fig. 6c). Neither SOX9 nor SOX2 expression were as-
sociated with poorer prognosis (data not shown).
Discussion
Extracapsular growth has become an important part of
oncological studies in the last years. The association of
ECG and poorer prognosis, both in gastric cancer [4] and
in gastrointestinal malignancies in general [3], turns the
parameter ECG into an interesting target for recent studies
regarding tumours of the gastrointestinal tract [5, 16, 17].
Its association with histomorphological parameters such as
TNM-category, lymphovascular invasion and tumour grad-
ing [6, 7] implies ECG to be a morphological marker for a
more aggressive biological phenotype of gastrointestinal
cancer. Recently, extranodal extension already became a
part of the lymph node category of head and neck cancer
staging systems [18, 19]. Therefore, there is huge evidence
that ECG should find access to tumour staging classifica-
tions of gastrointestinal malignancies in addition to the
established staging systems TNM and UICC.
Our results are in concordance with previously published
data. In this study, we could confirm ECG to be associated
with poorer prognosis and multivariate analysis identified
ECG to be an independent prognostic factor. In addition,
the yet known correlation of ECG and histomorphological
parameters could be retraced in this study as ECG was sig-
nificantly associated with higher pT- and pN- categories
and the presence of lymphovascular invasion. Thus, from
the accordance of our results with recently published data
it may be concluded that the results of this study are repre-
sentative for gastric cancer patients in general.
Since ECG seems to be a morphological marker for a
more aggressive tumour phenotype there may be an asso-
ciation of ECG with other markers for aggressive growth.
Of interest, we could not obtain a correlation of ECG and
Lauren classification, although diffuse-type carcinomas
are known to grow aggressively and to be associated with
bad prognosis [20]. Thus, it could be concluded that ECG
is more likely associated with intrinsic factors such as pro-
oncogenic properties of tumour cells. In this study, we
analysed two different markers associated with stem cell
features of tumour cells in the literature. As our data show
a significant correlation between ECG and the marker
SOX9, it could be assumed from our data that ECG
may be associated with stemness properties in gastric
cancer. SOX9 turned out to be an important stem
a b
c d
Fig. 5 Correlation of ECG with pT- (a) and pN-category (b), presence (pM1) or absence (pM0) of distant metastases (c) and with presence (L1) or
absence (L0) of lymphangiosis carcinomatosa (d) according to TNM-classification of malignant s (8th edition 2017)
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cell marker for gastrointestinal and other malignan-
cies. In mammary cell carcinoma, SOX9 is known to
be partly responsible for the determination of the
stem cell state by inducing epithelial mesenchymal
transition (EMT) [12], which is also known to play a
decisive role in the genesis of gastrointestinal tumours
[21, 22]. Furthermore, high SOX9 expression is asso-
ciated with advanced TNM category, poorer prognosis
and tumour progression, both in gastric cancer and
other types of gastrointestinal cancer [13–15, 23]. The
deletion of SOX9 results in an increased epithelial
proliferation and intestinal hyperplasia [10, 24].
Nevertheless, it remains controversial, whether SOX9
is a suitable stem cell marker in gastric cancer. In
our collection of gastric cancer patients we could
demonstrate a significant association of ECG and
SOX9 but no correlation between ECG and SOX2,
which is an established stem cell marker in gastric
cancer [25]. Thus, we could not proof a correlation
of EGC with a distinct stem cell phenotype. However,
it could be concluded from our data that SOX9 acts
as a pro-oncogene in gastric cancer and plays an im-
portant role in gastric cancer progression and forma-
tion of ECG in lymph node metastasis.
a b
c d
Fig. 6 Correlation of SOX9 and SOX2 expression with ECG and ICG (a, c) and with the presence or absence of lymph-node metastasis (b, d)
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In this study, the expression of SOX9 was neither associ-
ated with survival nor with pT- or pM-category which is
mainly due to the fact that our data primarily includes
nodal positive patients and is therefore biased. However,
our data did show a significant association of high SOX9
expression and nodal status and the presence of ECG.
From the fact that cases with extracapsular growth show
higher SOX9 expression it can be concluded that ECG is a
promising biomarker for a more aggressive gastric cancer
phenotype. Further studies, especially on molecular levels
need to be done in order to understand the functional and
biological aspects of ECG and the intrinsic significance and
exact mechanism of pro-oncogenes such as SOX9.
Conclusions
In summary, our data confirm that ECG is an independ-
ent prognostic factor and a potential morphological bio-
marker for a more aggressive phenotype in gastric
Table 2 Correlation of SOX9 expression with clinico-pathological parameters at time of surgery (according to TNM Classification of
Malignant Tumours 8th edition 2017). Percent-values are given in parentheses
SOX9
Characteristic Total (%) high positive negative p
All patients 211 (100) 175 (82.9) 36 (17.1)
Age (median. 66.5) years
≤ 66 104 (49.3) 81 (38.4) 23 (10.9) 0.054
≥ 67 107 (50.7) 94 (44.5) 13 (6.2)
Gender
Male 135 (64.0) 111 (52.6) 24 (11.4) 0.712
Female 76 (36.0) 64 (30.3) 12 (5.7)
Lauren classification
diffuse 74 (35.1) 58 (27.5) 16 (7.6) 0.290
intestinal 113 (53.6) 98 (46.4) 15 (7.1)
mixed type 24 (11.4) 19 (9.0) 5 (2.4)
Tumor size (UICC)
T0 4 (1.9) 2 (0.9) 2 (0.9) 0.286
T1 2 (0.9) 2 (0.9) 0 (0)
T2 96 (45.5) 81 (38.4) 15 (7.1)
T3 73 (34.6) 58 (27.5) 15 (7.1)
T4 35 (16.6) 31 (14.7) 4 (1.9)
Tx 1 (0.5) 1 (0.5) 0 (0)
Nodal status
N0 17 (8.1) 10 (4.7) 7 (3.3) 0.006
N+ 194 (91.9) 165 (78.2) 29 (13.7)
Capsule status of N+ cases
extra-capsular growth (ECG) 70 (33.2) 67 (31.8) 3 (1.4) 0.0003
intra-capsular growth (ICG) 124 (58.8) 98 (46.4) 26 (12.3)
Distant metastasis
M0 137 (64.9) 111 (52.6) 26 (12.3) 0.565
M1 58 (27.5) 49 (23.2) 9 (4.3)
Mx 16 (7.6) 15 (7.1) 1 (0.5)
Tumor grade (WHO)
G1 2 (0.9) 2 (0.9) 0 (0) 0.816
G2 31 (14.7) 26 (12.3) 5 (2.4)
G3 173 (82.0) 144 (68.2) 29 (13.7)
Gx 5 (2.4) 3 (1.4) 2 (0.9)
Significant results are indicated by bold numbers
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cancer. This is supported by the fact that ECG correlates
with the expression of SOX9 indicating that this bio-
marker probably plays an important role in the patho-
genesis of gastric cancer and ECG formation. Thus, it
could be concluded from our data that in gastric cancer
ECG, similar to tumour of the vulva and the head and
neck region, should be integrated in established cancer
staging systems such as TNM and UICC.
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